Skip to main navigation Skip to search Skip to main content

Anagram:A Phase 2, Multicenter, Randomized, Active-controlled Study to Assess the Safety and Efficacy of ANG003 at Two Different Dose Levels in Subjects with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis

Grants and Contracts Details

StatusActive
Effective start/end date6/26/26 → 6/26/28

Funding

  • Rho Incorporated: $2.00